| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/5584_2016_108 |
| P698 | PubMed publication ID | 27620306 |
| P2093 | author name string | Paolo Prandoni | |
| P2860 | cites work | Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q24633053 |
| Oral rivaroxaban for symptomatic venous thromboembolism | Q29620160 | ||
| Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review | Q33468803 | ||
| Risk of recurrent venous thromboembolism after a first oestrogen-associated episode. Data from the REVERSE cohort study | Q33601589 | ||
| Patients with a first symptomatic unprovoked deep vein thrombosis are at higher risk of recurrent venous thromboembolism than patients with a first unprovoked pulmonary embolism. | Q53767247 | ||
| Aspirin for dual prevention of venous and arterial thrombosis. | Q55056808 | ||
| D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study | Q56973674 | ||
| Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study | Q56989286 | ||
| Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia | Q57003501 | ||
| Dynamics of case-fatalilty rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism | Q57212683 | ||
| Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis | Q57616514 | ||
| Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials | Q33910755 | ||
| Bleeding risk in randomized controlled trials comparing warfarin and aspirin: a systematic review and meta-analysis | Q34132273 | ||
| Aspirin for preventing the recurrence of venous thromboembolism | Q34276812 | ||
| Low-dose aspirin for preventing recurrent venous thromboembolism | Q34309660 | ||
| D-dimer testing to determine the duration of anticoagulation therapy | Q34576728 | ||
| Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis | Q34603112 | ||
| Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism | Q34655742 | ||
| Dabigatran versus warfarin in the treatment of acute venous thromboembolism | Q35016336 | ||
| Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. | Q36550717 | ||
| Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy | Q36841584 | ||
| Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism | Q37288236 | ||
| Statin treatment and risk of recurrent venous thromboembolism: a nationwide cohort study | Q37293275 | ||
| Patient outcomes after deep vein thrombosis and pulmonary embolism: the Worcester Venous Thromboembolism Study | Q37389225 | ||
| Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism | Q37741638 | ||
| Statin use and the prevention of venous thromboembolism: a meta-analysis | Q37780572 | ||
| Residual venous thrombosis as predictive factor for recurrent venous thromboembolim in patients with proximal deep vein thrombosis: a sytematic review | Q37849816 | ||
| Statin use and venous thromboembolism recurrence: a combined nationwide cohort and nested case-control study. | Q38211112 | ||
| Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis | Q38439334 | ||
| Mild antithrombin deficiency and risk of recurrent venous thromboembolism: a prospective cohort study. | Q38442595 | ||
| Sex difference in risk of second but not of first venous thrombosis: paradox explained | Q39328528 | ||
| Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study | Q44181685 | ||
| Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V Leiden and prothrombin G20210A. | Q44196663 | ||
| Major bleeding as a predictor of mortality in patients with venous thromboembolism: findings from the RIETE Registry | Q44481789 | ||
| Statin treatment and the risk of recurrent pulmonary embolism. | Q44550160 | ||
| Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor | Q44852505 | ||
| Family history of venous thromboembolism (VTE) as a predictor for recurrent VTE in unprovoked VTE patients. | Q45160607 | ||
| Elevated D-dimer levels predict recurrence in patients with idiopathic venous thromboembolism: a meta-analysis. | Q46123639 | ||
| Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial | Q46368145 | ||
| Extended use of dabigatran, warfarin, or placebo in venous thromboembolism | Q46848170 | ||
| The risk of recurrent venous thromboembolism in men and women | Q47332296 | ||
| Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). | Q47923995 | ||
| Oral rivaroxaban for the treatment of symptomatic pulmonary embolism | Q49168967 | ||
| Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis | Q50143690 | ||
| D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. | Q50595629 | ||
| Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. | Q51574600 | ||
| Age at first venous thromboembolism and risk of recurrence: a prospective cohort study. | Q51603817 | ||
| Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. | Q51831890 | ||
| Unexpectedly high recanalization rate in patients with pulmonary embolism treated with anticoagulants alone. | Q53065926 | ||
| Non-OO blood type influences the risk of recurrent venous thromboembolism. A cohort study. | Q53088907 | ||
| Familial risk of venous thromboembolism in first-, second- and third-degree relatives: a nationwide family study in Sweden. | Q53117105 | ||
| A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. | Q53374794 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | anticoagulation | Q63279445 |
| P304 | page(s) | 89-100 | |
| P577 | publication date | 2016-09-13 | |
| P1433 | published in | Advances in Experimental Medicine and Biology | Q4686385 |
| P1476 | title | The Optimal Duration of Anticoagulation in Patients with Unprovoked Venous Thromboembolism. | |
| P478 | volume | 906 |
Search more.